Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut Català de la Salut | OTHER |
Not provided
Not provided
Not provided
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection.
OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19.
METHODS. Describe the rate of hospitalization, ICU, survival, postcovid syndrome and thrombosis among COVID 19 cases having antihistamines and amantadine as chronic treatments.
The rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with chronic treatment with antihistamines or amantadine | The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups. |
| |
| Other population of the THC | The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antihistamine | Drug | Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines |
| Measure | Description | Time Frame |
|---|---|---|
| Hospital Admissions. | Rate of Hospitalization among COVID 19 infections | from march 2020. |
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Survival among COVID1 hospitalized cases. | from march 2020 |
| Symptomatic infection | Patients suffering a symptomatic COVID19 infection within a determinate age group |
Not provided
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine -
Exclusion Criteria: None
-
Not provided
Not provided
Not provided
Not provided
Population assigned to the Public and free Access Terrassa Health Consortium
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anna Puigdellivol, Ph.D | Contact | 34-93-5884555 | apuigdellivol@cst.cat |
| Name | Affiliation | Role |
|---|---|---|
| Anna Puigdellívol, PhD | Terrassa Health Consortium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de Terrassa | Recruiting | Terrassa | Barcelona | 08227 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33465426 | Background | Moran Blanco JI, Alvarenga Bonilla JA, Homma S, Suzuki K, Fremont-Smith P, Villar Gomez de Las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients. Pulm Pharmacol Ther. 2021 Apr;67:101989. doi: 10.1016/j.pupt.2021.101989. Epub 2021 Jan 16. | |
| 33604795 |
Not provided
Not provided
Once the papers related to the study are published, a statement will be included offering data when contacting with the authors.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D006633 | Histamine Antagonists |
| D000547 | Amantadine |
| ID | Term |
|---|---|
| D018494 | Histamine Agents |
| D018377 | Neurotransmitter Agents |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Amantadine | Drug | Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine |
|
|
| from march 2020 |
| Postcovid syndrome | Patients developing postcovid syndrome after COVID19 infection | from april 2020 |
| Thrombosis | Patients developing thrombosis (with particular assessment of stroke, cardiac infarction, retinal vessels and pulmonary embolism) | from april 2020 |
| Hospital of Terrassa | Recruiting | Terrassa | Barcelona | 08227 | Spain |
|
| Cortes-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. 2021 Jun;73(3):962-965. doi: 10.1007/s43440-021-00231-5. Epub 2021 Feb 18. |
| 39770791 | Result | Puigdellivol-Sanchez A, Juanes-Gonzalez M, Calderon-Valdiviezo A, Losa-Puig H, Valls-Foix R, Gonzalez-Salvador M, Lozano-Paz C, Vidal-Alaball J. COVID-19 in Relation to Chronic Antihistamine Prescription. Microorganisms. 2024 Dec 13;12(12):2589. doi: 10.3390/microorganisms12122589. |
| 39459868 | Result | Puigdellivol-Sanchez A, Juanes-Gonzalez M, Calderon-Valdiviezo A, Valls-Foix R, Gonzalez-Salvador M, Lozano-Paz C, Vidal-Alaball J. COVID-19 in Relation to Polypharmacy and Immunization (2020-2024). Viruses. 2024 Sep 27;16(10):1533. doi: 10.3390/v16101533. |
| 41754542 | Result | Puigdellivol-Sanchez A, Arevalo-Genicio A, Garcia-Arque MC, Gragea-Nocete M, Lozano-Paz C, Moro-Casasola V, Perez-Diaz C, Valls-Foix R, Roca-Puig R, Llistosella M. Long COVID and Reduced Thrombosis in Antihistamine-Treated Patients: An Observational Study in the Metropolitan Area of Barcelona. Viruses. 2026 Feb 2;18(2):197. doi: 10.3390/v18020197. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D020164 | Chemical Actions and Uses |
| D045505 | Physiological Effects of Drugs |
| D000218 | Adamantane |
| D001952 | Bridged-Ring Compounds |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |